MIF and neoplasm: In this study, we evaluated if the combination of anti-MIF and anti–programmed cell death 1 (anti–PD-1) therapies could synergistically reduce tumor progression in the immune-responsive YUMMER1.7 melanoma and the MC38 colorectal carcinoma murine models.